| Endocrine-disrupting chemicals: an Endocrine Society scientific statement E Diamanti-Kandarakis, JP Bourguignon, LC Giudice, R Hauser, GS Prins, ... Endocrine reviews 30 (4), 293-342, 2009 | 5381 | 2009 |
| The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report R Azziz, E Carmina, D Dewailly, E Diamanti-Kandarakis, ... Fertility and sterility 91 (2), 456-488, 2009 | 2518 | 2009 |
| Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline R Azziz, E Carmina, D Dewailly, E Diamanti-Kandarakis, ... The Journal of Clinical Endocrinology & Metabolism 91 (11), 4237-4245, 2006 | 2392 | 2006 |
| Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications E Diamanti-Kandarakis, A Dunaif Endocrine reviews 33 (6), 981-1030, 2012 | 2072 | 2012 |
| A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile E Diamanti-Kandarakis, CR Kouli, AT Bergiele, FA Filandra, TC Tsianateli, ... The journal of clinical endocrinology & metabolism 84 (11), 4006-4011, 1999 | 1573 | 1999 |
| Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and … RA Wild, E Carmina, E Diamanti-Kandarakis, A Dokras, ... The Journal of Clinical Endocrinology & Metabolism 95 (5), 2038-2049, 2010 | 1300 | 2010 |
| The polycystic ovary syndrome: a position statement from the European Society of Endocrinology G Conway, D Dewailly, E Diamanti-Kandarakis, HF Escobar-Morreale, ... European journal of endocrinology 171 (4), P1-P29, 2014 | 936 | 2014 |
| Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary … R Azziz, E Carmina, D Dewailly, E Diamanti-Kandarakis, ... Fertil Steril 91 (2), 456-488, 2009 | 580 | 2009 |
| Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS E Kandaraki, A Chatzigeorgiou, S Livadas, E Palioura, F Economou, ... The Journal of Clinical Endocrinology & Metabolism 96 (3), E480-E484, 2011 | 521 | 2011 |
| Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS) A Dunaif, X Wu, A Lee, E Diamanti-Kandarakis American Journal of Physiology-Endocrinology and Metabolism 281 (2), E392-E399, 2001 | 515 | 2001 |
| Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome E Diamanti-Kandarakis, C Kouli, T Tsianateli, A Bergiele European Journal of Endocrinology 138 (3), 269-274, 1998 | 502 | 1998 |
| Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline R Azziz, E Carmina, D Dewailly, E Diamanti-Kandarakis, ... J Clin Endocrinol Metab 91 (11), 4237-4245, 2006 | 492 | 2006 |
| Exercise and the stress system G Mastorakos, M Pavlatou, E Diamanti-Kandarakis, GP Chrousos Hormones (Athens) 4 (2), 73-89, 2005 | 485 | 2005 |
| Molecular mechanisms of insulin resistance in polycystic ovary syndrome E Diamanti-Kandarakis, AG Papavassiliou Trends in molecular medicine 12 (7), 324-332, 2006 | 469 | 2006 |
| Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations MG Hayes, M Urbanek, DA Ehrmann, LL Armstrong, JY Lee, R Sisk, ... Nature communications 6 (1), 7502, 2015 | 397 | 2015 |
| Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome E Diamanti-Kandarakis, CD Christakou, E Kandaraki, FN Economou European journal of endocrinology 162 (2), 193-212, 2010 | 380 | 2010 |
| Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy E Diamanti-Kandarakis, G Spina, C Kouli, I Migdalis The Journal of Clinical Endocrinology & Metabolism 86 (10), 4666-4673, 2001 | 374 | 2001 |
| Pathophysiology and types of dyslipidemia in PCOS E Diamanti-Kandarakis, AG Papavassiliou, SA Kandarakis, GP Chrousos Trends in Endocrinology & Metabolism 18 (7), 280-285, 2007 | 373 | 2007 |
| Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications E Diamanti-Kandarakis Expert Reviews in molecular medicine 10, e3, 2008 | 368 | 2008 |
| The role of genes and environment in the etiology of PCOS E Diamanti-Kandarakis, H Kandarakis, RS Legro Endocrine 30, 19-26, 2006 | 344 | 2006 |
